Generated: April 27, 2017
|Title:||Unitary pharmaceutical dosage form|
|Abstract:||In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.|
|Inventor(s):||Dahl; Terrence C. (Sunnyvale, CA), Hussain; Munir A. (Belle Mead, NJ), Lipper; Robert A. (Pennington, NJ), Jerzewski; Robert L. (Belle Mead, NJ), Menning; Mark M. (San Francisco, CA), Oliyai; Reza (San Carlos, CA), Yang; Taiyin (Saratoga, CA)|
|Assignee:||Bristol-Myers Squibb & Gilead Sciences, Inc. (Foster City, CA)|
1. A method comprising administering to a patient in need of antiviral therapy a composition comprising a unitary dosage form comprising tenofovir DF in a first compartment and
a surfactant and efavirenz in a second compartment, wherein the first and second compartments are physically discrete but associated with and in physical contact with one another, and further comprising emtricitabine, and wherein the antiviral therapy is
2. The method of claim 1 wherein the dosage form is administered only once daily.